collection
MENU ▼
Read by QxMD icon Read
search

New trials

shared collection
2 papers 0 to 25 followers
https://www.readbyqxmd.com/read/25107913/phase-ii-study-of-bevacizumab-temozolomide-and-hypofractionated-stereotactic-radiotherapy-for-newly-diagnosed-glioblastoma
#1
Antonio Omuro, Kathryn Beal, Philip Gutin, Sasan Karimi, Denise D Correa, Thomas J Kaley, Lisa M DeAngelis, Timothy A Chan, Igor T Gavrilovic, Craig Nolan, Adilia Hormigo, Andrew B Lassman, Ingo Mellinghoff, Christian Grommes, Anne S Reiner, Katherine S Panageas, Raymond E Baser, Viviane Tabar, Elena Pentsova, Juan Sanchez, Renata Barradas-Panchal, Jianan Zhang, Geraldine Faivre, Cameron W Brennan, Lauren E Abrey, Jason T Huse
PURPOSE: Bevacizumab is associated with decreased vascular permeability that allows for more aggressive radiotherapy schedules. We conducted a phase II trial in newly diagnosed glioblastoma utilizing a novel hypofractionated stereotactic radiotherapy (HFSRT) schedule combined with temozolomide and bevacizumab. EXPERIMENTAL DESIGN: Patients with tumor volume ≤60 cc were treated with HFSRT (6 × 6 Gy to contrast enhancement and 6 × 4 Gy to FLAIR hyperintensity with dose painting) combined with concomitant/adjuvant temozolomide and bevacizumab at standard doses...
October 1, 2014: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/24171516/autologous-transplantation-as-consolidation-for-aggressive-non-hodgkin-s-lymphoma
#2
RANDOMIZED CONTROLLED TRIAL
Patrick J Stiff, Joseph M Unger, James R Cook, Louis S Constine, Stephen Couban, Douglas A Stewart, Thomas C Shea, Pierluigi Porcu, Jane N Winter, Brad S Kahl, Thomas P Miller, Raymond R Tubbs, Deborah Marcellus, Jonathan W Friedberg, Kevin P Barton, Glenn M Mills, Michael LeBlanc, Lisa M Rimsza, Stephen J Forman, Richard I Fisher
BACKGROUND: The efficacy of autologous stem-cell transplantation during the first remission in patients with diffuse, aggressive non-Hodgkin's lymphoma classified as high-intermediate risk or high risk on the International Prognostic Index remains controversial and is untested in the rituximab era. METHODS: We treated 397 patients who had disease with an age-adjusted classification of high risk or high-intermediate risk with five cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP plus rituximab...
October 31, 2013: New England Journal of Medicine
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"